Divi's Laboratories share news and announcements

NSE: DIVISLABBSE: 532488Pharmaceuticals & BiotechnologyLarge Cap

₹8,950.00₹212.00 (2.31%)BSE ₹8,984.00

Share price at the NSE close on 23 Oct 2026. Previous close ₹9,162.00.

52-week range of traded prices to 23 Oct 2026

₹5,647.50Low, 2 Apr 2026₹9,740.00High, 24 Sep 2026

Next results date: the board meets on 7 Nov 2026 to consider: financial results.

Market cap: ₹2,37,594 Cr50th largest listed
P/E: 81.2
P/B: 14.2
Dividend yield: 0.34%
ROE: 18.4%
ROCE: 20.8%
Debt to equity: 0.00
Volume, NSE: 6,20,26160.6% delivered

Divi's Laboratories share news and announcements

636 announcements, routine notices left out, newest first. Page 7 of 13.

Nov 2017
Oct 2017
- 31 Oct · Board meeting
  Outcome of Board Meeting held on October 31, 2017. (opens in a new tab)
- 31 Oct · Results
  Financial results for the period ended September 30, 2017. (opens in a new tab)
- 23 Oct · Board meeting
  To consider and approve, inter-alia, the un-audited financial results for the quarter and half-year ended September 30, 2017. (opens in a new tab)
Sep 2017
Aug 2017
Jul 2017
- 22 Jul · Management
  Appointment of Mr S. Ganapaty as Additional ( Independent) Director of the company w.e.f. July 22, 2017. (opens in a new tab)
- 22 Jul · Results
  Financial results for the period ended June 30, 2017. (opens in a new tab)
- 14 Jul · Board meeting
  Inter-alia, to consider and approve un-audited financial results for the quarter ended June 30, 2017. (opens in a new tab)
- 10 Jul · Updates
  USFDA to Lift Import Alert 99-32 on the Company's Unit-II at Visakhapatnam. (opens in a new tab)
Jun 2017
- 28 Jun · Board meeting
  Outcome of Board Meeting held on Jun 27, 2017.Pursuant to Regulation 30 of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, we wish to inform you that the Board of Directors at their meeting held on 27th June, 2017 has:1) Noted the completion of tenure of Mrs. S. Sridevi as an Independent Director of the company w.e.f. 22nd June, 2017 and hence she ceases to be a director of the company. The Board places on record its appreciation of the contribution made by Mrs. Sridevi during her tenure.2) Appointed Dr. Ramesh B. V. Nimmagadda as an Additional (Independent) Director w.e.f. 27th June, 20173) Appointed Ms. Nilima Motaparti, as an Additional (Whole-time) Director w.e.f. 27th June, 2017, who was earlier appointed by the members as Chief Controller (Commercial) in the year 2012.4) Noted that the term of the present Statutory Auditors M/s. PVRK Nageswara Rao & Co., expires at the conclusion of the ensuing 27th Annual General Meeting of the company as per Section 139 of the Companies Act, 2013, and are not eligible for re-appointment.5) Recommended appointment of M/s. Price Waterhouse, Chartered Accountants, as Statutory Auditors of the company for a term of 5 consecutive years from the conclusion of the 27th Annual General Meeting of the Company scheduled to be held in the year 2017 till the conclusion of 32nd Annual General Meeting, for approval of the members of the company. (opens in a new tab)
May 2017
Apr 2017
Mar 2017
Feb 2017
- 4 Feb · Results
  Financial results for the period ended December 31, 2016. (opens in a new tab)
Jan 2017
- 23 Jan · Board meeting
  To consider and approve, inter-alia, the un-audited financial results for the quarter and nine months ended December 31, 2016. (opens in a new tab)
- 9 Jan · Updates
  Vide letter dated January 09, 2017, regarding "Update on US-FDA inspection of our Unit-II at Visakhapatnam". (opens in a new tab)
Dec 2016
- 23 Dec · News Verification
  Exchange has sought clarification from Divi's Laboratories Limited with respect to recent news item captioned "Emkay says on Vizag 483 observation: 1. Proper control not being exercised over computer system 2. Facility equipments not maintained to ensure purity quality strength 3. Documentation and records not maintained or inaccurate falsified." The Exchange, in order to verify the accuracy or otherwise of the information reported in the media and to inform the market place so that the interest of the investors is safeguarded, had written to the company. Divi's Laboratories Limited has submitted their response. (opens in a new tab)
- 23 Dec · News Verification
  Exchange has sought clarification from Divi's Laboratories Limited with respect to recent news item captioned "Emkay says on Vizag 483 observation: 1. Proper control not being exercised over computer system 2. Facility equipments not maintained to ensure purity quality strength 3. Documentation and records not maintained or inaccurate falsified." In this regard, Exchange have advised the Company to provide clarification/confirmation on the news item in detail including the following: Whether you/company are aware of any information that has not been announced to the Exchanges which could explain the aforesaid movement in the trading. The response from the company is awaited.
- 7 Dec · Updates
  It s Unit-II at Visakhapatnam, Andhra Pradesh has had an inspection by the US-FDA from November 29, 2016 to December 06, 2016. The Company have been issued a form 483 with 5 observations and these shall be responded within the time permitted. (opens in a new tab)
Nov 2016
Aug 2016
Jul 2016
- 29 Jul · Meeting
  Register of Members & Share Transfer Books of the Company will remain closed from August 22, 2016 to August 26, 2016 (both days inclusive) for the purpose of Annual General Meeting (AGM) of the Company to be held on August 29, 2016. (opens in a new tab)
Jun 2016
- 7 Jun · Declaration for audit reports with unmodified opinion(s)
  Declaration mentioned in SEBI Circular CIR/CFD/CMD/56/2016. (opens in a new tab)
May 2016